Combo Treatment Beneficial in Biliary-Tract Cancer Study

MONDAY, Nov. 23 (HealthDay News) -- A new combination drug therapy shows promise in treating patients with advanced biliary-tract cancers, researchers say.

The study from the Massachusetts General Hospital Cancer Center in Boston found that survival and tumor response in patients treated with bevacizumab (Avastin), an angiogenesis inhibitor that has helped slow the growth of other cancers, in addition to the chemotherapy regimen of gemcitabine and oxaliplatin -- a combined treatment called GEMOX-B -- was comparable to findings in previous studies in which patients were treated with gemcitabine and oxaliplatin alone.

In the new phase 2 trial, 35 biliary-tract cancer patients were given all three drugs intravenously (bevacizumab at 10 milligrams per kilogram, followed by gemcitabine at 1,000 milligrams per square meter, and oxaliplatin at 85 milligrams per square meter) on days 1 and 15, every 28 days. Whole-body PET scans were used to assess patients at the start of the study and at the end of the second cycle of treatment.

The researchers found that the overall tumor response rate was 40 percent (14 patients with confirmed partial responses) and stable disease was noted in another 10 patients (29 percent). The overall survival was found to be 12.7 months, with a median progression-free survival of seven months. However, progression-free survival at six months was below the targeted rate at 63 percent, they noted.

The most common negative side effects of GEMOX-B therapy were fatigue, an abnormally low number of white blood cells, peripheral neuropathy, high blood pressure and gastrointestinal problems, but the therapy was generally well-tolerated, the study authors pointed out.

The findings add to increasing evidence "supporting the combination of molecularly targeted agents with chemotherapy to further improve treatment outcomes in patients with biliary-tract cancers," the researchers wrote.

The findings are published in the Nov. 22 online edition of The Lancet Oncology.

More information

The American Cancer Society explains bile duct cancer.

SOURCE: The Lancet Oncology, news release, Nov. 22, 2009

null
Join the Discussion
You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.
blog comments powered by Disqus
 
You Might Also Like...
See It, Share It
PHOTO: The scene near the finish line of the Boston Marathon is seen in this April 16, 2013 file photo. Inset, suspects Tamerlan and Dzhokhar Tsarnaev are seen. Tamerlan Tsarnaev died after a gunfight with police and Dzhokhar Tsarnaev, was captured.
Elise Amendola/AP Photo; Inset: Lowell Sun, FBI/AP Photo
PHOTO: The first explosion knocked down a runner at the finish line of the 117th Boston Marathon.
John Tlumacki/The Boston Globe via Getty Images
PHOTO: Pulaski Township Police Sgt. Chad Adam seen here in this undated Facebook photo, went undercover as an Amish woman.
Pulaski Township Police Department/Facebook
PHOTO: The Earths shadow is cast over the surface of the moon as a total lunar eclipse is seen though a Magnolia tree top in the sky over Tyler, Texas, April 15, 2014.
Dr. Scott M. Lieberman/AP Photo